Prosecution Insights
Last updated: April 19, 2026

Examiner: JONES, DAMERON LEVEST

Tech Center 3900 • Art Units: 1618 3991

This examiner grants 68% of resolved cases

Performance Statistics

67.5%
Allow Rate
+7.5% vs TC avg
1112
Total Applications
+31.4%
Interview Lift
1310
Avg Prosecution Days
Based on 1068 resolved cases, 2023–2026

Rejection Statute Breakdown

0.3%
§101 Eligibility
5.5%
§102 Novelty
28.7%
§103 Obviousness
25.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19375848 B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF Non-Final OA Aktis Oncology, Inc.
17630286 CELL PENETRATING PEPTIDE FUNCTIONALIZED PERFLUOROCARBON NANOEMULSION COMPOSITIONS AND METHODS FOR IMAGING CELL POPULATIONS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18424371 PEPTIDE LIBRARIES WITH NON-CANONICAL AMINO ACIDS Final Rejection Regeneron Pharmaceuticals, Inc.
17770464 COMPOSITIONS COMPRISING MODIFIED SMARCB1 AND USES THEREOF Final Rejection Dana-Farber Cancer Institute, Inc.
17730130 REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES Non-Final OA University of Washington
18041470 TEXAPHYRIN DERIVATIVES FOR MANGANESE CHEMOTHERAPY, PHOTOACOUSTIC IMAGING, AND PHOTOTHERMAL THERAPY Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17782147 COMBINATION THERAPIES FOR THE TREATMENT OF CANCER Non-Final OA Board of Regents, The University of Texas System
17663133 LUNG TARGETED ANTICANCER THERAPIES WITH LIPOSOMAL ANNAMYCIN Final Rejection Board of Regents, The University of Texas System
17782908 INFLAMMATION-RESPONSIVE ANTI-INFLAMMATORY HYDROGELS Non-Final OA Nanyang Technological University
18036579 PROBES, SYSTEMS, AND METHODS FOR MAGNETIC RESONANCE PH SENSING Non-Final OA The General Hospital Corporation
18676138 PRE-TARGETING STRATEGIES FOR MOLECULAR IMAGING AND/OR RADIOIMMUNOTHERAPY Final Rejection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
18773055 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer Non-Final OA Advanced Accelerator Applications International SA
18350268 TOPICAL APPLICATION OF NERVE LABELING DYES FOR IMAGE-GUIDED SURGERY Non-Final OA EDISON INNOVATION, LLC
17606254 COMPOSITIONS AND METHODS OF IMMUNODEPLETION FOR THE TREATMENT OF MALIGNANT AND NON-MALIGNANT HEMATOLOGICAL DISEASES Final Rejection ACTINIUM PHARMACEUTICALS, INC.
18689166 ATHEROSCLEROSIS-TARGETED LIPOSOME NANOCARRIER DELIVERY SYSTEM AND PREPARATION METHOD THEREFOR Non-Final OA Beijing Inno Medicine Co., Ltd.
17627805 ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF Non-Final OA INSTITUTE OF BASIC MEDICAL SCIENCES, CHINESE ACADEMY OF MEDICAL SCIENCES
17769657 METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY Non-Final OA NIHON MEDI-PHYSICS CO., LTD.
18041532 COMPOUNDS AND COMPOSITIONS FOR TUMOR DETECTION AND SURGICAL GUIDANCE Non-Final OA Molecular Targeting Technologies, Inc.
17786768 ANTI-HER2 POLYPEPTIDES DERIVATIVES AS NEW DIAGNOSTIC MOLECULAR PROBES Non-Final OA BRACCO IMAGING S.P.A.
17789398 RADIOLABELED PEPTIDES FOR NON-INVASIVE DIAGNOSIS AND TREATMENT OF CXCR4 EXPRESSING TUMORS Non-Final OA ISTITUTO NAZIONALE TUMORI IRCCS - FONDAZIONE G. PASCALE
17779732 POLYETHYLENE GLYCOL CONJUGATE DRUG, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Non-Final OA CHONGQING UPGRA BIOTECHNOLOGY CO., LTD.
17773759 CARBON QUANTUM DOTS AND USES THEREOF Non-Final OA CNANO MEDICINE CORP.
17767956 FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT Final Rejection Collagen Medical, LLC
17579909 Method of Treatment of Neuroendocrine Tumors That Over-Express Somatostatatin Receptors Non-Final OA ADVANCED ACCELERATOR APPLICATIONS
17618850 COMPOUNDS AND METHODS OF USE Final Rejection EDINBURGH MOLECULAR IMAGING LIMITED

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month